At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 44 enrolled
Drug / intervention
Pfs25 VLP- FhCMBbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1 Study of the Safety and Immunogenicity of Plant-Derived Pfs25 VLP-FhCMB Malaria Transmission Blocking Vaccine in Healthy Adults
Fraunhofer, Center for Molecular Biotechnology·interventional·Posted Dec 17, 2013·Updated Mar 8, 2017
In Brief
A Phase 1 clinical trial evaluating Pfs25 VLP- FhCMB for Malaria. Completed, enrolled 44 participants across 1 site.
Detailed Summary
This study is a Phase 1, dose escalation, first-in-human study designed primarily to evaluate the safety of the purified plant-derived Pfs25 VLP combined with Alhydrogel adjuvant
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMalaria
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartOct 2013
First PostedDec 2013
Primary CompletionAug 2014
Study CompletionJan 2015
TodayJul 2026
First PostedDec 17, 2013
Enrollment StartOct 1, 2013
Primary CompletionAug 1, 2014
Study CompletionJan 1, 2015
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 12.5 years ago
Interventions
Pfs25 VLP- FhCMBbiological